Indian Stocks signal
SUNPHARMA

SUNPHARMA

Sun Pharmaceutical Industries Limited · Healthcare

Indian StocksDrug Manufacturers - Specialty & GenericNSIINR-11.8% from ATH
Current Price

$1,764.00

Drawdown from ATH

-11.8%

Last Updated

Oct 16, 2026

Dipsern Grade90d

D

Weak

Graded against SUNPHARMA's own history at this drawdown — not the market's.

What it means: SUNPHARMA's own history does not strongly favor buying at this level yet.

What to do: Consider watching and waiting for a deeper dip or a higher grade.

Median 90-Day Return
Historical Win Rate
Last 30 days+4.39%
Oct 2Nov 13
About SUNPHARMA

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orth

The reading

How Dipsern reads SUNPHARMA right now.

Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.

Snapshot

How is SUNPHARMA doing right now?

In plain terms: SUNPHARMA is 11.8% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.

Sun Pharmaceutical Industries Ltd. (SUNPHARMA) sits 11.8% off its peak and is currently in a moderate correction, last printing at $1,764. A drawdown of this depth is where patient buyers start paying attention. Historically the asymmetry begins to favor accumulation here, especially when paired with structural demand.

Historical base rate

What history says at this drawdown

SUNPHARMA reaches this drawdown band repeatedly in its history (954 observations), which is a large sample for the segmentation engine to compute a stable median forward return. The engine uses a rolling 90-day window and gives more weight to recent years — this lets the signal adapt to regime changes (e.g., post-COVID volatility) without losing the long-run base rate.

Interpretation

What this means for SUNPHARMA

Drawdown-based signals work across asset classes but the magnitude of meaningful moves varies. Dipsern computes the segmentation per-asset so the bands are calibrated to SUNPHARMA's own volatility history. Moderate corrections are the highest-information zone for the Dipsern signal: enough drawdown for mean-reversion to matter, not so much that fundamentals are likely broken. Watch the prediction-error column — if past signals at this level were accurate, the current one is more trustworthy.

Comparable signals

Other Indian Stocks at similar drawdown levels

Five tickers closest to SUNPHARMA's distance from all-time high. Same category, one tap away.

Pidilite Industries Ltd.

-11.5% from ATH

Solar Industries India Ltd.

-11.5% from ATH

Zydus Lifesciences Ltd.

-11.3% from ATH

Apollo Hospitals Enterprise Ltd.

-13.0% from ATH

Dr. Reddy's Laboratories Ltd.

-13.2% from ATH

Historical depth

Sample sizes by drawdown band

Dipsern segments the full drawdown range into 20 equal-width bands. The table shows the number of confirmed historical observations in each band for SUNPHARMA. Median forward returns, win rates, and prediction errors are available in the full analysis.

Drawdown BandObservationsMedian ReturnWin Rate
-75% to -70%5
-70% to -65%60
-65% to -60%258
-60% to -55%265
-55% to -50%270
-50% to -45%212
-45% to -40%473
-40% to -35%462
-35% to -30%387
-30% to -25%381
-25% to -20%328
-20% to -15%513
Methodology

Every grade is reproducible.

We segment 40+ years of SUNPHARMA's price history into 20 equal-width drawdown bands and compute forward median returns, win rates, and prediction error per band. No look-ahead bias. Pure NumPy. Open math, gated numbers.

Years of history

40+

Drawdown bands

20

Look-ahead bias

None

Data sources

4

Unlock SUNPHARMA's full analysis

See the Dipsern grade, median returns, win rates, prediction accuracy, 8 interactive charts, historical price paths, and a plain-English verdict for SUNPHARMA.

Dipsern is research and a second opinion — not a broker. You'd buy SUNPHARMA at your own broker.

Analyze SUNPHARMA Free

No credit card required · 5 free analyses per month

Signal computed Oct 16, 2026 using default parameters (90-day return period, 20 segments, 0.95 decay). Data sourced from Yahoo Finance, Binance, CoinGecko, and Steam Market.